The regulatory setback occurred when the U.S. Food and Drug Administration issued a Complete Response Letter regarding the company's bitopertin program. Federal regulators cited significant uncertainties within the new drug application, explicitly stating that the submission lacked the necessary evidence to warrant approval. This rejection prompted an immediate market reaction, wiping out nearly a quarter of the firm's valuation in a single trading session.
Investors Scrutinize Disc Medicine Following FDA Rejection
A 22% drop in Disc Medicine stock on February 13, 2026, has triggered a formal investigation by the Rosen Law Firm. The legal action centers on allegations that the biotechnology company provided misleading business information to shareholders following the FDA’s decision to block its bitopertin drug application.
Rosen Law is now soliciting inquiries from affected investors to determine the viability of a class action suit. The firm argues that shareholders may be eligible for compensation for losses incurred during the period in question. Interested parties are directed to register via the firm’s online portal or contact attorney Phillip Kim directly. While the firm emphasizes its historical record in securities litigation and multi-million dollar settlements, the investigation remains in the early stages as legal counsel evaluates the extent of the alleged misrepresentations.
Comments (0)
No comments yet. Be the first!